Abscisic acid (ABA) is a phytohormone recently identified as a new endogenous pro-inflammatory hormone in human granulocytes. Here we report the functional activation of human monocytes and vascular smooth muscle cells by ABA. Incubation of monocytes with ABA evokes an intracellular Ca 2؉ rise through the second messenger cyclic ADP-ribose, leading to NF-B activation and consequent increase of cyclooxygenase-2 expression and prostaglandin E 2 production and enhanced release of MCP-1 (monocyte chemoattractant protein-1) and of metalloprotease-9, all events reportedly involved in atherogenesis. Moreover, monocytes release ABA when exposed to thrombin-activated platelets, a condition occurring at the injured vascular endothelium; monocyte-derived ABA behaves as an autocrine and paracrine pro-inflammatory hormone-stimulating monocyte migration and MCP-1 release, as well as vascular smooth muscle cells migration and proliferation. These results, and the presence of ABA in human arterial plaques at a 10-fold higher concentration compared with normal arterial tissue, identify ABA as a new signal molecule involved in the development of atherosclerosis and suggest a possible new target for anti-atherosclerotic therapy.
Abscisic acid (ABA) is a phytohormone recently identified as a new endogenous pro-inflammatory hormone in human granulocytes. Here we report the functional activation of human monocytes and vascular smooth muscle cells by ABA. Incubation of monocytes with ABA evokes an intracellular Ca 2؉ rise through the second messenger cyclic ADP-ribose, leading to NF-B activation and consequent increase of cyclooxygenase-2 expression and prostaglandin E 2 production and enhanced release of MCP-1 (monocyte chemoattractant protein-1) and of metalloprotease-9, all events reportedly involved in atherogenesis. Moreover, monocytes release ABA when exposed to thrombin-activated platelets, a condition occurring at the injured vascular endothelium; monocyte-derived ABA behaves as an autocrine and paracrine pro-inflammatory hormone-stimulating monocyte migration and MCP-1 release, as well as vascular smooth muscle cells migration and proliferation. These results, and the presence of ABA in human arterial plaques at a 10-fold higher concentration compared with normal arterial tissue, identify ABA as a new signal molecule involved in the development of atherosclerosis and suggest a possible new target for anti-atherosclerotic therapy.
ABA
2 is an isoprenoid phytohormone regulating several physiological functions in Metaphyta, including response to abiotic stress (1) , and in lower Metazoa, where ABA mediates temperature-induced oxygen consumption and water filtration in sponges (2) and light-stimulated tissue regeneration in hydroids (3) . Recently, human granulocytes have been demonstrated to be activated by ABA through a signaling pathway sequentially involving a pertussis toxin (PTX)-sensitive receptor-G protein complex, activation of adenylyl cyclase, cAMP overproduction, PKA-mediated phosphorylation of the ADPribosyl cyclase (ADPRC) CD38, increase of the intracellular concentration of cADPR ([cADPR] i ), a Ca 2ϩ -mobilizing second messenger (4) , and increase of the intracellular calcium concentration ([Ca 2ϩ ] i ) (5) . The ABA-induced [Ca 2ϩ ] i rise activates reactive oxygen species and nitric oxide release, phagocytosis, and chemotaxis toward ABA (5) . The increase of intracellular ABA in heat-stressed granulocytes and ABA release by these cells during phagocytosis indicate that ABA behaves as a new human pro-inflammatory hormone.
Monocytes play a key role in both inflammation and immunity by performing antigen presentation, phagocytosis, and immunomodulation through the production of various cytokines and growth factors (6) . In atherosclerosis, a chronic immune inflammatory disease, the interaction between monocytes, platelets, and injured luminal endothelium is a crucial event leading to the atherosclerotic lesion of the arterial intima (7, 8) . Platelets trigger atherogenesis through adhesion to damaged endothelial cells and release of pro-inflammatory mediators, recruiting circulating monocytes to the site of the lesion (9) . Monocytes attach to and penetrate the vessel wall, where they undergo transformation into macrophages and eventually into foam cells (10) . At the site of the atherosclerotic lesion, monocytes/macrophages, platelets, and endothelial cells release chemoattractants, growth factors, and cytokines, which stimulate VSMC proliferation and migration into the sub-endothelium. Thrombus organization, extracellular matrix synthesis, and VSMC proliferation eventually lead to the development of the atheromatous plaque (7) (8) (9) (10) . Here we investigate the effect of ABA on human monocytes and VSMC and its possible role in the activation of cell responses known to be responsible for atherogenesis.
EXPERIMENTAL PROCEDURES
Materials-FURA-3PE/AM, protein kinase inhibitors (protein kinase A inhibitor peptide sequence 14 -22, cell-permeant, myristoylated; protein kinase C inhibitor peptide sequence 20 -28, cell-permeant, myristoylated), and Ro 20-1724 were purchased from Calbiochem. SYTOX Green, Alexa-streptavidin, and calcein-AM were obtained from Molecular Probes (Eugene, OR). Cell culture media were from Cambrex Bio Science (Walkersville, MD). Ficoll-Paque Plus, [ 3 H](Ϯ)-ABA (40 Ci/mmol), MCP-1 Elisa kit, and cAMP radioimmunoassay kit were from GE Healthcare. All antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA), except for the anti-ABA monoclonal antibody (mAb), which was from Agdia (Elkart, IN). PGE 2 monoclonal EIA kit was from Cayman Chemical Co. (Ann Arbor, MI); chemotaxis chambers (ChemoTx system microplates) were from NeuroProbe (Gaithersburg, MD). (Ϯ)-cis,trans-ABA and all other chemicals were obtained from Sigma. Biotinylated ABA (bio-ABA) was prepared as described (5) .
Isolation of Human Monocytes-Mononuclear cells, isolated by Ficoll-Paque sedimentation from fresh buffy coats, were seeded in tissue culture dishes in Dulbecco's modified Eagle's medium (DMEM). After 6 h, adherent monocytes were washed and cultured in DMEM with 10% autologous plasma, penicillin (100 units/ml), and streptomycin (100 g/ml) (monocyte medium).
Fluorimetric [Ca 2ϩ ] i Measurements- [Ca 2ϩ ] i measurements were performed on FURA-3PE/AM-loaded monocytes seeded on 20-mm glass coverslips as described in Ref. 11 .
Determination of Intracellular cAMP ([cAMP] i ) and [cADPR] i -Monocytes (2 ϫ 10
6 /assay) were preincubated in Hanks' balanced salt solution (HBSS) for 5 min at 37°C with 10 M cAMP phosphodiesterase inhibitor 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) and, when indicated, for 45 min with 2 g/ml PTX. After incubation with or without 10 M ABA for 0, 30, 60, and 150 s, cells were scraped in 300 l of distilled water, and the reaction was stopped with 20 l of 9 M perchloric acid at 4°C. The [cAMP] i was determined by radioimmunoassay. For determination of the [cADPR] i , monocytes (2 ϫ 10 6 /assay) were incubated for 0, 5, 15, and 60 min at 25°C without (control) or with 10 M (Ϯ)-, (ϩ)-, or (Ϫ)-cis,trans-ABA. At each time point, a 500-l aliquot of the cell suspension was withdrawn and centrifuged at 5,000 ϫ g for 15 s; cell pellets were lysed in 300 l of 0.6 M perchloric acid at 4°C and centrifuged, and the cADPR content was measured (12) .
Assay of GDP-ribosyl Cyclase (GDPRC) Activity-Monocytes were resuspended in HBSS (2 ϫ 10 6 /ml), and ectocellular GDPRC activity was measured in the presence or absence (control) of 10 M ABA as described in Ref. 5 .
NF-B Nuclear Translocation-Monocytes (3 ϫ 10 6 /dish), incubated without (control) or with ABA or cADPR for 30 min, were resuspended in 400 l of ice-cold buffer A (20 mM TrisHCl, pH 7.8, 50 mM KCl, 10 g/ml leupeptin, 0.1 M dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) and 400 l of buffer B (buffer A containing 1.2% Nonidet P-40), vortexed for 10 s, and centrifuged at 14,000 ϫ g for 30 s at 4°C, and supernatants were discarded. Pelleted nuclei were washed once with buffer A, resuspended in 100 l of buffer B, sonicated (10 s at 3 watts), and centrifuged at 14,000 ϫ g for 20 min at 4°C. Supernatants were recovered, and 40 g of nuclear proteins per sample were subjected to 10% SDS-PAGE and Western blot. Densitometric analysis was performed using the Chemi-Doc System (BioRad). Values are expressed as a luminescence increase relative to control, untreated cells, and normalized on RNA polymerase II.
COX-2 Expression, PGE 2 Production, and MCP-1 Release in Monocytes-Monocytes (3 ϫ 10 6 /dish) were incubated for 6 h without (control) or with ABA or cADPR. Where indicated, cells were pretreated for 45 min with 50 M Wedelolactone (WT). After incubation, the culture medium was recovered for quantification of PGE 2 production and MCP-1 release; adherent cells were washed three times with ice-cold phosphatebuffered saline and lysed with 400 l of lysis buffer (100 mM dithiothreitol, 2% SDS, 10% glycerol, and 50 mM Tris-HCl, pH 6.8). Forty g of cell extract per sample were subjected to 10% SDS-PAGE, Western blot, and densitometric analysis (ChemiDoc System). Values are expressed as increase relative to control, untreated cells, and are normalized on actin. PGE 2 production or MCP-1 release in the culture media were quantified using PGE 2 per well) were incubated in HBSS with 10 M bio-ABA, in the presence or absence of excess unlabeled ABA (1 mM), for 5 min on ice. Cells were then washed in HBSS and incubated for a further 5 min on ice with 5 g/ml Alexa 488-conjugated streptavidin. Controls included cells incubated with Alexa 488-conjugated streptavidin alone and cells incubated first with 10 mM biotin, washed, and then incubated with Alexa 488-conjugated streptavidin. Monocytes were then seeded on 8-well chambered coverglasses at a cell density of 5 ϫ 10 6 per well. Images were obtained with a Leica TCS SL confocal microscope, equipped with Argon/He-Ne laser sources and a HCXPL APO CS 63.0 ϫ 1.40 oil objective. During image acquisition, laser energy was set at 25%, emission range was between 500 and 600 nm, and the photomultiplier voltage gain was set to eliminate cell autofluorescence. Z-stacks of 50 sections were taken with a Z-step of 122 nm for a total thickness of 5.5-6 m. Average projections were calculated using Leica LCS software.
Stimulation of Monocytes with Thrombin-activated PlateletsFreshly prepared washed platelets (13) (WP) in Ca 2ϩ -and Mg 2ϩ -free HBSS were pelleted by centrifugation (500 ϫ g for 20 min), resuspended at 2 ϫ 10 8 /ml in Ca 2ϩ -HBSS, and incubated with 0.25 unit/ml thrombin. After 30 min at 37°C, hirudin (0.5 unit/ml) was added to inactivate thrombin (14) , and the platelet suspension was mixed with an equal volume of monocyte medium (PT medium); 2 ml of PT medium was transferred onto 2 ϫ 10 6 monocytes seeded in 10 ϫ 35-mm dishes (final platelet density, 10 8 /ml). After 1 h of incubation at 37°C, the supernatant was collected, centrifuged at 13,000 ϫ g for 3 min, and either used in autocrine/paracrine stimulation experiments (MPT medium) or extracted to determine the ABA content.
ABA Release from Monocytes-Monocytes (2 ϫ 10 6 /dish) were cultured for 60 min at 39 or at 37°C without (control, unstimulated) or with thrombin-activated platelets (10 8 /ml final concentration) or 50 ng/ml MCP-1. The culture supernatant was recovered, centrifuged (2,200 ϫ g for 10 min), and extracted with 4 volumes of distilled methanol. The monocyte layer was washed with 2 ml of HBSS, harvested in 0.5 ml of HBSS, and extracted in 2 ml of distilled methanol. Acid extraction of ABA and measurement of the ABA content by HPLCcoupled mass spectrometry or by a sensitive (lower limit of detectability, 3 fmol of ABA) and specific enzyme-linked immunosorbent assay kit were performed as described (5) .
Monocyte Migration-Monocytes were detached with EDTA, washed, and resuspended at 10 7 /ml in DMEM. Twenty five l of the cell suspension were placed in the upper well of chemotaxis chambers, and cells were allowed to migrate through 5-m pore membranes toward the lower well containing the following: 50 ng/ml MCP-1; 0.001, 0.1, 1, or 10 M ABA; 0.1 M ABA and 0.1 g/ml anti-ABA mAb; the supernatant of unstimulated monocytes (M medium); the supernatant of platelet-activated monocytes (MPT medium), without or with 0.1 g/ml anti-ABA mAb; and the supernatant of thrombinactivated platelets (PT medium). The plates were incubated for 90 min at 37°C, and transmigrated cells were quantified as described (5) .
Cell Culture-Human aortic smooth muscle cells (AoSMC) obtained from Cambrex Bio Science at passage 3 were seeded in 75-cm 2 flasks and cultured at 37°C in a 5% CO 2 -humidified atmosphere in Smooth Muscle Growth medium (SMC medium) containing smooth muscle cell bullet kit, 100 units/ml penicillin, and 100 g/ml streptomycin. Cells were harvested with trypsin/EDTA. All experiments were performed on cells at passage 4 -8.
Autocrine Effects of ABA on Monocyte Release of MCP-1, PGE 2 , and MMP-9-Monocytes (2 ϫ 10 6 /dish) were cultured for 3 h in M medium (control) or MPT medium, preincubated for 45 min without or with 0.1 g/ml anti-ABA mAb. MMP-9 was quantified with the human cytokine antibody array (RayBiotech Inc., Milan, Italy).
AoSMC Migration-Two different assays were employed as follows: (i) migration across a freshly scraped subconfluent monolayer; (ii) migration through 8-m pores of polycarbonate filters, toward a chemoattractant (chemotaxis) or toward medium (chemokinesis). For the first assay, AoSMC were trypsinized and seeded at a density of 4 ϫ 10 4 cells/well on 8-well chamber slides in SMC medium. After 24 h, the medium was replaced with serum-free DMEM for 24 h to arrest growth. Sub-confluent AoSMC monolayers were linearly scratched with a micropipette tip; detached cells were removed by washing, and adherent cells were incubated for 6 h in SMC medium without (control) or with 25 ng/ml platelet-derived growth factor-BB (PDGF-BB) or 100 nM ABA. The number of cells migrated into the scraped area was evaluated by phase contrast microscopy. Chemotaxis and chemokinesis assays were performed using 96-well ChemoTx microplates. AoSMC were resuspended at 1 ϫ 10 6 /ml in chemotaxis buffer (HBSS, phosphate-buffered saline, and 5% albumin, 39:16:1), and 25 l of the cell suspension was placed on top of the filter, and cells were challenged to migrate toward SMC medium containing exogenous ABA or toward M or MPT medium, preincubated or not with 0.1 g/ml anti-ABA mAb. For chemokinesis assays, cells were preincubated for 20 min at 37°C with the same stimuli used for chemotaxis and then challenged to migrate toward either SMC medium, in the experiments testing exogenous ABA, or monocyte-conditioned medium, in the experiments testing monocyte-produced ABA. The plates were incubated for 2 h at 37°C, and transmigrated cells were quantified as described previously (5).
AoSMC Proliferation-AoSMC were seeded in 96-well plates (3 ϫ 10 3 cells/well) in SMC medium. After 24 h, the medium was replaced with DMEM without serum, and cells were cultured for a further 24 h to arrest growth. Cells were then exposed for 24 h to the following media: 100 l of DMEM without additions (control); DMEM containing 10 ng/ml PDGF-BB; DMEM containing 10 or 100 nM ABA without or with 0.1 g/ml anti-ABA mAb; M, PT, or MPT medium, without or with 0.1 g/ml anti-ABA mAb. After 24 h, the medium was removed; cells were washed with phosphate-buffered saline and incubated for 20 min at 37°C in HBSS containing 2.5 M calcein-AM and then washed with HBSS; fluorescence was quantified on a FLUOstar OPTIMA fluorimeter (BMG Labtechnologies, Germany) at 488 nm. Cell numbers were calculated from a standard curve, obtained in parallel by seeding known cell numbers.
ABA Content in Human Carotid Plaques-Freshly isolated arterial segments, obtained during vascular surgery, were immediately placed in ice-cold distilled methanol; samples included segments (ϳ80 mg wet weight) of carotid arteries (common and/or internal) either with macroscopic plaques or apparently intact, and segments of macroscopically non-atheromatous aorta and mesentheric or femoral arteries. Vessel segments were dissected into 1-2-mm pieces and sonicated in 1 ml of distilled methanol (four times for 20 s at 3 watts) in ice. The methanol aliquots of the sonication steps were pooled for each sample, and extraction of ABA was performed as described (5) . The ABA content in the extracts was measured by enzyme-linked immunosorbent assay. Results are expressed as picomoles of ABA per mg wet weight of the arterial segment. ] i increased from a basal value of 50 Ϯ 4 to 70 Ϯ 5, 66 Ϯ 2, 75 Ϯ 5, and 98 Ϯ 3 nM, respectively (Fig. 1A , trace 1 shows response to 10 M ABA), whereas 1 nM ABA was without effect. When 10 M ABA was added to monocytes in Ca 2ϩ -free HBSS in the presence of extracellular EGTA, the sustained Ca 2ϩ elevation was strongly reduced (Fig. 1A, trace 2) , demonstrating that influx of extracellular Ca 2ϩ is primarily responsible for the ABA-induced [Ca 2ϩ ] i increase. The membrane-permeant cADPR antagonist 8-Br-cADPR (15) inhibited the ABA-induced [Ca 2ϩ ] i increase by 80 Ϯ 3% (Fig. 1A, trace 3 cle cells (19) , the fact that xestospongin C and U73122 inhibit the ABA-induced Ca 2ϩ elevation to a similar and limited extent suggests absence of a significant inhibition by xestospongin C of endoplasmic reticulum Ca 2ϩ uptake. The simultaneous presence of 8-Br-cADPR and U73122, or preincubation of intact monocytes with 2 g/ml PTX, abrogated the ABA-induced [Ca 2ϩ ] i rise (Fig. 1A , traces 4 and 5, respectively). The ADPRC CD38 was shown to be phosphorylated and activated by PKA in ABA-stimulated granulocytes (5) . In agreement with this finding, the [cAMP] i in human monocytes increased from an unstimulated value of 11.3 Ϯ 1.2 to 26.8 Ϯ 1.5 pmol/mg 30 s after the addition of 10 M ABA. Preincubation of the cells with 2 g/ml PTX prevented the ABA-induced increase of the [cAMP] i (Fig. 1B) . CD38 is expressed in human monocytes (20) ; in agreement with the rapid increase of the [cAMP] i induced by ABA, the GDPRC activity measured on nicotinamide guanine dinucleotide, oxidized, as a NAD ϩ surrogate substrate (21) increased by 40% after 5 min of incubation of the cells with ABA, from a basal value of 0.51 Ϯ 0.13 to 0.7 Ϯ 0.14 nmol/min/mg (n ϭ 5, p Ͻ 0.05). Conversely, no increase of the GDPRC activity was observed in cells preincubated for 45 min with the PKA-specific inhibitor and then challenged with ABA.
RESULTS

ABA Induces a Sustained, cADPR-dependent
Involvement of cADPR in the ABA-induced Ca 2ϩ response was confirmed by the increase of the [cADPR] i upon stimulation of monocytes with 10 M ABA (Fig. 1C) To reproduce the Ca 2ϩ signaling induced by ABA through the use of its second messengers, membrane-permeant 8-BrcAMP or exogenous cADPR was added to human monocytes. cADPR can enter several cell types across multiple nucleoside transporters, both equilibrative and concentrative (ENT and CNT, respectively) (22) , which are expressed on human monocytes (23). 8-Br-cAMP (5 M) or cADPR (100 M) both induced a slow and sustained [Ca 2ϩ ] i increase in human monocytes (inset to Fig. 1A) .
Nuclear Translocation of NF-B in ABA-treated Monocytes-NF-B regulates the expression of several inflammatory proteins in monocytes. In response to inflammatory stimuli, cytosolic NF-B translocates into the nucleus via a Ca 2ϩ -and PKC-dependent phosphorylation of the NF-B inhibitor IB (24) . Incubation of monocytes for 30 min with increasing ABA concentrations determined a dose-dependent nuclear translocation of NF-B, the highest values (2.17-fold increase over control) being observed with 10 M ABA (Fig. 1D) .
Thus, we investigated whether extracellular cADPR could mimic the effect of ABA on NF-B translocation. In agreement with its apparent role as the second messenger of ABA (Fig. 1, A and C) , cADPR stimulated nuclear translocation of NF-B (1.6-fold higher than in untreated controls; Fig. 1D ). Moreover, pretreatment of monocytes with 8-Br-cADPR prior to exposure to ABA reduced nuclear translocation of NF-B by ϳ70% ( Table 1) .
The ABA-induced NF-B nuclear translocation was abrogated by pretreatment of monocytes with the intracellular calcium chelator 100 M EGTA-AM (data not shown), or with 5 mM EDTA, or with a membrane-permeant PKC-specific inhibitor peptide (Table 1) . Moreover, PTX (2 g/ml) inhibited the ABA-induced nuclear translocation of NF-B by 90 Ϯ 2% (Table 1) , in agreement with its abrogation of the ABA-induced [Ca 2ϩ ] i rise (Fig. 1A) . Finally, the PKA-specific inhibitor also abrogated the ABA-triggered nuclear translocation of NF-B (Table 1) (27) . These genes are known to play an important role in the development of the atherosclerotic lesion. Western blot of monocyte extracts showed that COX-2 expression was increased 1.3-, 1.4-, and 1.6-fold compared with control, untreated cells after exposure of the cells for 6 h to 0.1, 1.0, and 10 M ABA, respectively ( Fig. 2A) . COX-2 levels were similarly increased 1.6-fold over control values in monocytes incubated for 6 h with 10 M cADPR ( Fig. 2A) . EDTA, the PKCand PKA-specific inhibitor peptides, 8-Br-cADPR and PTX, all of which prevented the ABA-induced NF-B translocation, also abrogated ABA-induced COX-2 overexpression (Table 1) .
COX-2 catalyzes the first step of the synthesis of PGE 2 , an important mediator of inflammation and arterial thrombosis (28) . PGE 2 release from monocytes incubated for 6 h with ABA was already maximally stimulated (1.8-fold over untreated cultures) by as low as 0.1 M ABA (Fig. 2B) . Incubation with ABA for 30 min, a time frame sufficient to induce NF-B translocation (Fig. 1D) , followed by its removal exerted a similar stimulatory effect on PGE 2 release as the continuous presence of the hormone (Fig. 2B) .
Stimulation of PGE 2 release by ABA was abrogated in the presence of either of the following compounds: EDTA, the peptide inhibitor of PKC or of PKA, 8-Br-cADPR, or PTX ( Table 1) . Incubation of monocytes with 10 M cADPR also stimulated PGE 2 release (1.4-fold over control cultures, see tion with ABA or cADPR, abrogated the stimulation of PGE 2 production (Fig. 2B) .
Incubation of monocytes for 6 h with increasing ABA concentrations dose-dependently stimulated release of MCP-1, the highest cytokine level (2.3-fold increase over control cultures) being observed with 10 M ABA (Fig. 2C) . Incubation with ABA for 30 min followed by its removal exerted a similar stimulatory effect on MCP-1 release as the continuous presence of the hormone (Fig. 2B) . The ABA-induced stimulation of MCP-1 release was almost completely inhibited (by 94, 88, and 90%) by preincubation of monocytes with the PKC-or the PKA-specific inhibitor or with 8-Br-cADPR, respectively, and was abrogated by pretreatment of monocytes with EDTA or with PTX ( Table   1) . Incubation of cells with 10 M cADPR for 6 h also increased MCP-1 release (1.9-fold over controls, see Fig. 2C ); preincubation of monocytes with WT prior to stimulation with either ABA or cADPR abrogated their effect on MCP-1 production (Fig. 2C) .
Finally, the effect of ABA on monocyte release of MMP-9, a zinc protease involved in extracellular matrix remodeling during atherosclerosis (30), was investigated. Gelatin zymography showed a 1.8-fold increase of active (i.e. gelatinolytic) MMP-9 in the supernatant of monocytes incubated for 6 h with 10 M ABA compared with untreated controls (Fig. 2D) . Together, these data indicate that ABA induces overexpression in human monocytes of NF-B-controlled, atherosclerosis-related proteins through a signaling pathway involving cADPR as second messenger.
Binding of ABA to Monocytes-PTX abolished all biochemical responses triggered by ABA on monocytes, suggesting the presence of G protein-coupled ABA-binding sites on the plasma membrane. Bio-ABA has been used to demonstrate ABA-binding sites on the plasma membrane of stomatal guard cells (31) and of human granulocytes (5). Surface fluorescence was indeed detected on monocytes incubated with bio-ABA and subsequently with fluorescein isothiocyanateconjugated streptavidin (Fig. 3A) , and excess unconjugated ABA prevented cell staining (Fig. 3B) .
ABA Production and Release by Monocytes-ABA was detected by HPLC-mass spectrometry in extracts of monocytes at 4.11 Ϯ 0.82 pmol/mg protein (n ϭ 6), i.e. at a concentration more than 1 log higher than that observed in granulocytes (0.23 Ϯ 0.09 pmol/mg) (5). When human monocytes were incubated for 60 min at 39°C, the [ABA] i was not significantly modified, but ABA release into the medium was increased (3.6 Ϯ 0.6-fold over controls, incubated at 37°C, see Fig. 4A ). Stimulation by exogenous ABA of monocyte release of pro-atherogenic PGE 2 , MCP-1, and MMP-9 prompted us to investigate whether the interaction between monocytes and activated platelets, a crucial event occurring on the injured vascular endothelium, could induce ABA release from monocytes. Thus, monocytes (2 ϫ 10 6 in 2 ml) and thrombin-activated platelets (10 8 /ml, a density similar to that occurring in blood) were co-incubated for 1 h; as shown in Fig. 4A , platelets remarkably stimulated ABA release from monocytes (9.2 Ϯ 0.7-fold increase over unstimulated monocytes) and also increased the [ABA] i (1.6 Ϯ 0.5-fold over controls). Platelet-derived ABA was less than 1.5% of that released by monocytes, as measured on the supernatant from thrombin-activated platelets in the absence of monocytes. Finally, incubation of monocytes with MCP-1 (50 ng/ml) for 60 min induced both an increase of the [ABA] i (2.7 Ϯ 0.3-fold over untreated controls) and of ABA release (2.8-fold over controls) (Fig. 4A) . Autocrine Effects of ABA on Monocytes-Release of ABA by monocytes stimulated by heat stress, platelets, or MCP-1 prompted us to investigate a possible autocrine/paracrine effect of ABA on monocytes. Human monocytes migrated through 5-m pore filters toward 100 nM ABA, with a chemotactic index (CI ϭ 1.5; Fig. 4B ) slightly lower than that toward MCP-1 (CI ϭ 1.9, a value similar to what was already reported; see Ref. 32) . Migration toward 100 nM ABA was reduced by 40% in the presence of 0.1 g/ml anti-ABA mAb (Fig. 4B) . A chemotactic response similar to that evoked by exogenous ABA was also observed when MPT medium was placed in the lower well of the chemotaxis chamber. Interestingly, preincubation of MPT medium with the anti-ABA mAb reduced chemotaxis by 63% (Fig. 4B) . Conversely, M medium (the supernatant of monocytes in the absence of added platelets) only slightly stimulated monocyte chemotaxis (CI ϭ 1.3), probably due to the presence of a small number of contaminating platelets, adhering to monocytes, as a result of the cell purification process. MPT medium but not M medium also induced the release from target monocytes of MCP-1, PGE 2 , and MMP-9; this release was inhibited by 50, 70, and 60%, respectively, when the conditioned medium was preincubated with the anti-ABA mAb prior to addition to target monocytes (Fig. 4C) .
ABA Stimulates Human AoSMC Migration and ProliferationAoSMC migration and proliferation are critical events in atherogenesis (33) . AoSMC migration was evaluated both by counting the number of cells migrated into the denuded area of a scratched monolayer and by evaluating the CI and the chemokinesis index (KI) in migration chambers.
In the denuded areas of AoSMC monolayers incubated for 6 h after wounding with 10 M ABA or with 25 ng/ml PDGF-BB, the most potent activator of AoSMC migration (34), the cell densities were 36 Ϯ 3 and 49 Ϯ 2 cells/mm 2 , respectively, whereas no cells were present in the denuded area of untreated samples (Fig. 5A) .
When 0.1 or 10 M ABA was placed in the bottom well of a migration chamber, AoSMC migrated toward ABA with a CI of 2.1 Ϯ 0.3 and 2.3 Ϯ 0.4, respectively (Fig. 5B-a, bars 1 and 2) . The untargeted cell movement (chemokinesis) of AoSMC placed on the filter of a chamber containing chemotaxis buffer in the bottom well was also stimulated by preincubation of the cells with 0.1 or 10 M ABA (the KI of ABA-treated cells was 2.7 Ϯ 0.5 and 4.0 Ϯ 0.2, respectively; Fig. 5B-b, bars 1 and 2) .
Finally, ABA stimulated AoSMC proliferation, with 0.01 and 0.1 M ABA inducing a 1.3-and 1.6-fold increase of AoSMC proliferation over untreated controls. PDGF-BB (10 ng/ml), a known stimulator of AoSMC proliferation, induced a 1.7-fold increase over controls (Fig. 5C ). The effect of 0.1 M ABA was already maximal because 10 M ABA did not further increase proliferation (data not shown). Incubation with ABA for 2 h followed by its removal exerted a similar stimulatory effect on AoSMC proliferation as the continuous presence of the hormone (Fig. 5C ). Thus, a short term exposure to ABA of both monocytes and AoSMC is sufficient to induce long term functional responses (PGE 2 and MCP-1 release from monocytes, Fig. 2 , B and C, and AoSMC proliferation, Fig. 5C ).
Paracrine Effects of Monocyte-released ABA on AoSMC Migration and Proliferation-To investigate whether ABA released from monocytes could stimulate AoSMC migration and proliferation, AoSMC were cultured in M or MPT medium and preincubated for 45 min without or with 0.1 g/ml anti-ABA mAb prior to addition to AoSMC.
As shown in Fig. 5B , MPT medium (bar 4), but not M medium (bar 3), stimulated AoSMC chemotaxis (Fig. 5B-a) and chemokinesis ( Fig. 5B-b) , and this effect was reduced (by 40 Ϯ 3 and 45 Ϯ 5% for CI and KI, respectively) by pretreatment of the conditioned medium with the anti-ABA mAb (bars 5). As a control, the anti-ABA mAb alone was without effect (Fig. 5B,  a-b, bar 6) .
After 24 h of incubation with MPT medium, the number of AoSMC increased 2.2-fold over controls (cultured in unconditioned DMEM), a more pronounced effect than that observed with PT medium, which induced a 1.4-fold increase of cell number over controls (Fig. 5C) . The stimulatory effect of PT medium on AoSMC proliferation may be attributed to PDGF release by activated platelets (35) . Preincubation of MPT medium with the anti-ABA mAb reduced its stimulatory effect on AoSMC proliferation by 50% (Fig. 5C) , similarly to what was observed upon addition of anti-ABA mAb to cultures containing 100 nM extracellular ABA (Fig. 5C) .
These results suggested the presence of ABA-binding sites on AoSMC. Indeed, incubation of AoSMC with bio-ABA and subsequently with fluorescein isothiocyanate-conjugated streptavidin revealed membrane fluorescence (Fig. 3C) , which was prevented by excess unconjugated ABA (Fig. 3D) .
ABA Content Is Higher in Human Carotid Plaques Compared with Normal Arteries-The genes encoding for MCP-1 and MMP-9 have been demonstrated to be transcribed in the atherosclerotic plaque (36) , and this observation has strengthened the conclusion that they play a causal role in the development of atherosclerosis. Thus, the presence of ABA in human atherosclerotic plaques was explored.
The ABA content in macroscopically atherosclerotic carotid (common and internal) arteries was compared with that in apparently intact segments of similar weight from the abdominal aorta and from the carotid, femoral, and mesentheric arteries. The ABA content of the atherosclerotic segments showed wide inter-individual variations (0.007-0.074 pmol/mg wet weight), but the average value was significantly higher compared with that measured in apparently unaffected arterial segments (0.023 Ϯ 0.018 versus 0.003 Ϯ 0.002 pmol/mg wet weight, respectively) ( Table 2) .
DISCUSSION
Extracellular ABA binds to a PTX-sensitive G protein-receptor complex on the monocyte plasma membrane, as demonstrated by toxin-mediated abrogation of the ABAinduced increase of the [Ca 2ϩ ] i and of the [cAMP] i (Fig. 1, A and B) and by membrane staining with bio-ABA (Fig. 3) . Downstream of the G protein-receptor complex, activation of both PKC and PKA occurs, as demonstrated by the inhibitory effect of the PKC-and of the PKAspecific inhibitors on several ABAtriggered effects as follows: NF-B translocation, PGE 2 and MCP-1 release (Table 1) , and stimulation of A/GDPRC activity (see under "Results"). PKA, activated by the ABA-triggered [cAMP] i rise (Fig.  1B) , stimulates A/GDPRC, inducing overproduction of cADPR (Fig. 1C) and a cADPR-mediated influx of extracellular Ca 2ϩ , as demonstrated by the near complete (80%) inhibition of the [Ca 2ϩ ] i rise observed with EDTA and with 8-Br-cADPR (Fig. 1A) . PKC activation apparently occurs through the following mechanisms ( Fig. 6 ): (i) the largely cADPR-dependent [Ca 2ϩ ] i increase, and (ii) to a comparatively lower extent, the ABA-induced activation of PLC, indicated by the fact that both the PLC inhibitor U73122 and 8-Br-cADPR are needed to abrogate the ABAinduced [Ca 2ϩ ] i increase (Fig. 1A) . The functional effects downstream of the [Ca 2ϩ ] i rise are dependent on the activation of NF-B following its nuclear translocation (Fig. 1D) . The causal role of the cADPR-mediated [Ca 2ϩ ] i increase and of PKC activation in NF-B translocation is demonstrated by its almost complete inhibition by 8-BrcADPR, by extracellular EDTA, or by the PKC-specific inhibitor (Table 1) . NF-B nuclear translocation in turn activates COX-2 expression ( Fig. 2A) and PGE 2 production (Fig. 2B ) and the release of MCP-1 and MMP-9 (Fig. 2, C and D) ; these transcriptional effects of ABA are prevented by preincubation of monocytes with WT, a specific NF-B inhibitor (Fig. 2, B and  C) . The fact that a maximal stimulation by ABA of PGE 2 release already occurs at 100 nM of the hormone (Fig. 2B) whereas the maximal stimulation of COX-2 expression requires 10 M ABA seems to indicate that PGE 2 release does not increase linearly with COX-2 expression levels, as already observed in murine macrophages (37) .
When exposed to thrombin-activated platelets, as occurs at the site of injured luminal endothelium, human monocytes release ABA (Fig. 4A) , which behaves as a chemoattractant for monocytes (Fig. 4B and Fig. 6 ) with a typical bell-shaped chemotaxis response to increasing concentrations of the chemoattractant (38 -41) . Monocyte-produced ABA also stimulates migration and proliferation of AoSMC (Fig. 5, A and B and Fig. 6 ). The cell types involved in this paracrine loop (activated platelets, monocytes, and AoSMC), the cell functions activated by ABA on AoSMC (migration and proliferation) and on monocytes (cytokine release and migration), and the cytokines released by ABA-stimulated monocytes (PGE 2 MCP-1 and MMP-9), all are known to play fundamental roles in the development of the atherosclerotic lesion. PGE 2 is known to stimulate synthesis of hyaluronic acid, the matrix polysaccharide principally involved in vascular remodeling, through up-regulation of hyaluronic acid synthase in VSMC (42) . Moreover, PGE 2 stimulates aggregation of submaximally stimulated platelets and facilitates the initiation of arterial thrombosis (28) . MMP-9 catalyzes the proteolytic cleavage of the extracellular matrix, which favors monocyte extravasation and VSMC migration through the blood vessel wall (30) .
MCP-1 is believed to be the primary chemoattractant for monocytes to the atherosclerotic plaque and stimulates VSMC proliferation (43) . The pivotal pathogenetic role of MCP-1 in the development of experimental restenosis, atherosclerosis, and plaque destabilization has been demonstrated in vivo through the use of peptide antagonists (44) and of anti-MCP-1 gene therapy (45) . Moreover, a specific polymorphism in the MCP-1 gene promoter, resulting in greater production of the cytokine, has been recently shown to be associated with increased risk of coronary atherosclerosis (46) . Finally, absence of MCP-1 protects transgenic mice from developing atherosclerosis (47) . Taken together, these results provide compelling evidence for a critical role of MCP-1 in initiating atherosclerosis through the recruitment of monocytes at the injured vessel Addition of an irrelevant mAb was without effect (data not shown). C, proliferation of AoSMC was evaluated after the following treatments: incubation for 24 h with DMEM without serum, in the absence (control) or in the presence of 10 ng/ml PDGF-BB, 10 or 100 nM ABA, without (white bars) or with (gray bar) 0.1 g/ml of anti-ABA mAb, or with the anti-ABA mAb alone (Ab-ABA); incubation for 24 h with M or MPT medium, without or with (gray bar) 0.1 g/ml anti-ABA mAb, or with PT; incubation for 2 h with 10 or 100 nM ABA, followed by 22 h in the absence of ABA (black bars). Results are the mean Ϯ S.D. of Ն3 experiments. §, p Ͻ 0.05, 100 nM ABA compared with 100 nM ABA with anti-ABA mAb; #, p Ͻ 0.01, MPT compared with MPT with anti-ABA mAb; *, p Ͻ 0.005, MPT compared with PT. Addition of an irrelevant mAb was without effect (data not shown). M, supernatant of unstimulated monocytes; MPT, supernatant of platelet-activated monocytes; PT, supernatant of thrombin-activated platelets.
TABLE 2 ABA content in human carotid plaques
The ABA content of segments of carotid (common and internal) arteries with macroscopic plaques is compared with that of segments of apparently intact carotid ( c ), aorta ( a ), femoral ( f ), and mesenteric ( m ) arteries (control). ABA content in the extracts was measured with a sensitive and specific enzyme-linked immunosorbent assay kit. ND indicates not detectable. ] i increase in turn activates NF-B nuclear translocation, which can be prevented by 8-Br-cADPR, EDTA, and by the PKC-and PKA-specific inhibitors iPKC and iPKA. Downstream of NF-B activation, transcription of COX-2, MCP-1, and MMP-9 is stimulated; these transcriptional effects are prevented by the NF-B-specific inhibitor WT. Release of PGE 2 , MCP-1, and MMP-9 following stimulation of monocytes with thrombin-activated platelets can be largely prevented by addition of an anti-ABA mAb to the monocyte culture medium. Release of MCP-1 stimulates autocrine ABA production, generating a positive feedback mechanism. Paracrine circuit, ABA released from platelet-activated monocytes stimulates AoSMC proliferation and migration. These paracrine effects can be prevented by addition of an anti-ABA mAb to the monocyte-conditioned culture medium.
